Trends in hip fracture epidemiology in Australia: Possible impact of bisphosphonates and hormone replacement therapy

被引:63
作者
Fisher, A. A. [1 ,2 ]
O'Brien, E. D. [1 ]
Davis, M. W. [1 ,2 ]
机构
[1] Canberra Hosp, Dept Geriatr Med, Woden, ACT 2606, Australia
[2] Australian Natl Univ, Sch Med, Canberra, ACT, Australia
关键词
Hip fracture; Epidemiology; Bisphosphonates; Hormone replacement therapy; AGE-ADJUSTED INCIDENCE; ESTROGEN PLUS PROGESTIN; NEW-SOUTH-WALES; OSTEOPOROSIS TREATMENT; OLDER PATIENTS; UNITED-STATES; INTERVENTION THRESHOLDS; HOSPITAL ADMISSIONS; INCIDENCE RATES; LIFETIME RISK;
D O I
10.1016/j.bone.2009.04.244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The purposes of this study were to analyse trends in hip fracture (HF) epidemiology over a 13-year period (1994-2007) in the Australian Capital Territory (ACT), to assess the potential impact of concurrent changes in hormone replacement therapy (HRT) and bisphosphonate use and to present a new prediction of HFs in Australia up to 2021. Annual sex- and age-specific incidence rates (per 100,000 population) were determined and standardized using the Australian 2006 population. The projected number of HFs was estimated by two models applying age- and sex-specific HF rates averaged for 2002-2006 (model I) or continuously changing as observed in this period (model 2, Poisson regression) to the projected population. In 2006 compared to 2001, the population :60 years in the ACT increased by 19.7%. Over the last 5 years the average annual incidence HF rate compared to the previous 3-year period decreased in females >= 60 years of age by 28.3%. Between 2001 and 2006 the number of prescriptions for HRT dispensed in the ACT declined by 54.6, while the number of prescriptions for bisphosphonate increased by 245%, accompanied by a decline in standardized incidence of HF rates of 36.4%, mainly in women (42.1%). This represents an annual cost for bisphosphonates per one prevented HF, of $A45,250 or $A576 person/year. Compared to 2006 the total number of HFs in Australia according to model I will increase in 2011 by 20.1% and in 2021 by 58.8%, but according to model 2 will decrease by 15.5% in 2011 and 27.5% in 2021. Our data suggest that the previously predicted rising trend in HFs in elderly women reversed, but did not so for men. This was coincident with a significant fall in HRT use and increased prescribing of bisphosphonates, which is cost-effective. However caution should be used in attributing causation as this is an ecological study. If trends in HF observed in 2002-2006 continue, the absolute number of HFs in Australia in 2011-2021 will stabilise or decline (which is more likely), despite the rapid ageing of the population. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:246 / 253
页数:8
相关论文
共 93 条
[1]   Epidemiology of hip fracture in the elderly in Spain [J].
Alvarez-Nebreda, M. Loreto ;
Jimenez, Ana Belen ;
Rodriguez, Paz ;
Serra, Jose Antonio .
BONE, 2008, 42 (02) :278-285
[2]   Theory and practice in medical statistics [J].
Amitage, P .
STATISTICS IN MEDICINE, 2001, 20 (17-18) :2537-2548
[3]  
*AUSTR BUR STAT, 2008, AUSTR DEM STAT POP P
[4]  
*AUSTR GOV DEP HLT, 2007, AUSTR STAT MED 1997
[5]   Trends in hospital admissions for fractures of the hip and femur in England, 1989-1990 to 1997-1998 [J].
Balasegaram, S ;
Majeed, A ;
Fitz-Clarence, H .
JOURNAL OF PUBLIC HEALTH MEDICINE, 2001, 23 (01) :11-17
[6]   Geographical variations in hip fracture risk for women: strong effects hidden in standardised ratios [J].
Barbier, S. ;
Ecochard, R. ;
Schott, A. -M. ;
Colin, C. ;
Delmas, P. D. ;
Jaglal, S. B. ;
Couris, C. M. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (03) :371-377
[7]  
Beral Valerie, 2003, Lancet, V362, P419
[8]  
Beringer T R O, 2006, Ulster Med J, V75, P200
[9]   Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance [J].
Boonen, S. ;
Vanderschueren, D. ;
Venken, K. ;
Milisen, K. ;
Delforge, M. ;
Haentjens, P. .
JOURNAL OF INTERNAL MEDICINE, 2008, 264 (04) :315-332
[10]   Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies [J].
Boonen, S ;
Laan, RF ;
Barton, IP ;
Watts, NB .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (10) :1291-1298